Citius Pharmaceuticals, Inc.
CTXR
$0.58
-$0.02-3.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.49M | 1.67M | 3.94M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.49M | 1.67M | 3.94M | -- | -- |
| Cost of Revenue | 491.80K | 328.90K | 789.20K | -- | -- |
| Gross Profit | 1.00M | 1.34M | 3.15M | -- | -- |
| SG&A Expenses | 9.96M | 30.18M | 10.00M | 6.80M | 7.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.51M | 32.14M | 12.39M | 8.44M | 8.79M |
| Operating Income | -10.01M | -30.47M | -8.45M | -8.44M | -8.79M |
| Income Before Tax | -12.03M | -28.34M | -9.13M | -8.48M | -8.94M |
| Income Tax Expenses | -107.30K | -231.20K | 264.20K | 264.20K | 264.20K |
| Earnings from Continuing Operations | -11.92M | -28.11M | -9.39M | -8.74M | -9.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 3.06M | 6.88M | 1.17M | 784.40K | 414.00K |
| Net Income | -8.86M | -21.23M | -8.22M | -7.96M | -8.79M |
| EBIT | -10.01M | -30.47M | -8.45M | -8.44M | -8.79M |
| EBITDA | -- | -29.90M | -7.87M | -8.44M | -8.79M |
| EPS Basic | -0.34 | -0.95 | -0.38 | -0.46 | -0.80 |
| Normalized Basic EPS | -0.13 | -0.54 | -0.19 | -0.26 | -0.47 |
| EPS Diluted | -0.34 | -0.95 | -0.38 | -0.46 | -0.80 |
| Normalized Diluted EPS | -0.13 | -0.54 | -0.19 | -0.26 | -0.47 |
| Average Basic Shares Outstanding | 26.17M | 22.38M | 21.50M | 17.20M | 11.01M |
| Average Diluted Shares Outstanding | 26.17M | 22.38M | 21.50M | 17.20M | 11.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |